Genetic Technologies Limited (GENE) Return on Sales by Net Profit

GENE (gtglabs.com) - company brandmark

Genetic Technologies generates revenue streams through its unique GeneType tests, which enable the preemptive detection of diabetes and cancer. The net profit margin confirms the profitability trend, where -156.80 represents the latest metric reading. The company is scaling B2B sales via the insurance sector, aiming to integrate polygenic risk scores into personalized medicine standards for the early detection of pathologies.

gtglabs.com (GENE) - Company Sales Margin from 07/04/2022 to 10/26/2024

Genetic Technologies Ltd (GENE) - metric breakdowns and financial figures

- share price and expert price forecast:
Fundamental company valuation:Genetic Technologies Ltd - GENE
Finished products of Genetic Technologies Limited

Sales margin reflects the share of net profit in total revenue, measuring the efficiency of converting income into final capital. Investors utilize this metric to assess business resilience against operating expenses and inflationary shocks. By analyzing the final sales margin, one can observe the dependence of Genetic Technologies (GENE) profitability on service scaling. Current profit volatility is directly linked to the process of integrating genetic tests into US and Australian medical protocols. Growth in this indicator would confirm the commercial viability of the company's model.